Understanding this difference is important when evaluating GLP-1 dosing strategies in menopause
A dedicated cardiovascular outcomes trial (SURPASS-CVOT) comparing tirzepatide to dulaglutide is ongoing, with results not yet published
Methods We searched for eligible trials published in PubMed (last search in February 2015) by using the following search algorithm: (Glucagon-like peptide-1 receptor agonists OR exenatide OR liraglutide OR lixisenatide OR albiglutide OR dulaglutide) AND (side effects OR adverse effects OR safety OR gastrointestinal OR pancreas OR liver OR cardiovascular OR skin OR allergy OR angioedema OR immune system OR renal OR kidney OR infection OR central nervous system OR blood OR malignancy OR cancer) The search was limited by the following criteria: - Published in the English language
Semaglutide has a longer track record in the area of medical weight loss, but tirzepatide is coming off as a strong contender for those who want a more aggressive approach
First, SELECT was designed as a CV outcomes trial and not a weight-loss trial, and weight loss was only a supportive secondary endpoint in the trial design
While its not clear whether the drugs pose harm to human pregnancy, Ross said, widespread educational efforts are needed as a precaution. This can happen through public awareness campaigns or extra messaging in the drugs marketing materials, he added, including drug labels, ads, and packaging
